Sun Pharma March-quarter net profit rises 57 percent

Thu May 29, 2014 6:56pm IST

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014. REUTERS/Danish Siddiqui

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014.

Credit: Reuters/Danish Siddiqui

Related Topics

Stocks

   
Rajalakshmi (C), 28, smiles after winning the Miss Wheelchair India beauty pageant in Mumbai November 26, 2014. REUTERS/Danish Siddiqui

Miss Wheelchair India

Seven women from across India participated in the country's second wheelchair beauty pageant, which aims to open doors for the wheelchair-bound in modelling, film and television, according to organisers  Slideshow 

REUTERS - Sun Pharmaceutical Industries Ltd (SUN.NS), India's third-largest drugmaker by revenue, on Thursday reported a 57 percent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.

The company, which is in the process of acquiring loss-making rival Ranbaxy Laboratories Ltd (RANB.NS), posted a net profit of 15.87 billion rupees ($269.55 million) in January-March, compared with 10.12 billion rupees a year earlier. Analysts on average expected 15.74 billion rupees, according to Thomson Reuters data.

Sales in January-March rose 32 percent to 40.44 billion rupees. The company also said it expects a 13 to 15 percent growth in sales in full-year 2015.

Sun Pharma, a bellwether in India's $15-billion pharmaceutical industry, agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd (4568.T) for $3.2 billion, creating the world's fifth-largest maker of generic drugs.

The drugmaker, however, faces an uphill task in turning around Ranbaxy's business and fixing manufacturing quality issues that have resulted in several Ranbaxy plants being barred from exporting to the United States.

Sun Pharma is also working towards resolving quality control issues that got its Karkhadi, India, plant banned by the U.S. Food and Drug Administration in March.

The company's shares, which are up 4 percent so far this year, ended 0.43 percent higher, while the Nifty was down 1.3 percent.

($1 = 58.8750 rupees)

(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)

FILED UNDER:

SAARC Summit

REUTERS SHOWCASE

E-Commerce Boom

E-Commerce Boom

Online grocers come up trumps in India's e-commerce boom   Full Article 

Reuters Poll

Reuters Poll

GDP growth to slow to 5.1 pct, but no rate cut yet  Full Article 

Oil Prices Fall

Oil Prices Fall

Oil at four-year low as OPEC production cut looks unlikely  Full Article 

Google in Europe

Google in Europe

Insight - Behind Google's Europe woes, American accents  Full Article 

Vodafone Tax Dispute

Vodafone Tax Dispute

India advised against challenging Vodafone tax ruling - source  Full Article 

India-focused Funds

India-focused Funds

India-focused hedge funds up over 40 pct YTD - HFR  Full Article 

Trade Deal

Trade Deal

WTO postpones trade deal by a day after last-minute objection.  Full Article 

RBI Rate Hopes

RBI Rate Hopes

Markets pricing in rate cut, despite wary RBI  Full Article 

Land Disputes

Land Disputes

Disputes over land for industry on the rise in India, angering locals - charities  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage